+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
COLINZ COLINZ

Colinz Laboratories Share Price

₹65.50 -2 (-2.96%)
25.49% Fall from 52W High

18 Nov, 2026 4:01 PM (IST)

Colinz Laboratories live price: ₹65.50. It opened at ₹68 vs previous close ₹68; intraday high/low: ₹68/₹66. The 50 & 200 DMA stand at ₹70.40/₹64.80.

Colinz Laboratories Performance

  • Today's Low
  • ₹66
  • Today's High
  • ₹68
  • 52 Week Low
  • ₹37
  • 52 Week High
  • ₹88
  • Open Price₹68
  • Previous Close₹68
  • Volume4
  • 50 DMA₹70.40
  • 100 DMA₹69.40
  • 200 DMA₹64.80

Colinz Laboratories Chart

Investment Returns

  • Over 1 Month -6.43%
  • Over 3 Month -18.12%
  • Over 6 Month + 45.36%
  • Over 1 Year + 52.11%

Smart Investing Starts Here Start SIP with Colinz Laboratories for Steady Growth!

Invest Now

Colinz Laboratories Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 5.9
  • PEG Ratio
  • 0
  • Market Cap Cr
  • 17
  • P/B Ratio
  • 1.3
  • Average True Range
  • 3.2
  • EPS
  • 11
  • Dividend Yield
  • 0
  • MACD Signal
  • -0.9
  • RSI
  • 41.72
  • MFI
  • 59.97

Latest Stock News Updates

Colinz Laboratories Ltd - 531210 - Announcement under Regulation 30 (LODR)-Newspaper Publication

Dear sir, Please find the attached News Paper Publication as required under Regulation 47(3) of SEBI(LODR), 2015. for the Quarter and Half year ended on 30-9-2026. Kindly take the same on records. For Colinz Labs Ltd Director

Colinz Laboratories Ltd - 531210 - Outcome Of The Board Meeting Under Regulation 30 And 33 Of SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015.

The Attached Results for Quarter ended on 30-9-2026 was approved in Bopard Meeting held on 29-10-2026 as required under Regulation 30 and 33 and our Auditors have issued Limited Review Report on the same. Kindly take the same on records. For Colinz Labs Ltd Director

Colinz Laboratories Ltd - 531210 - Board Meeting Outcome for Outcome Of The Board Meeting Under Regulation 30 And 33 Of SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015.

We would like to inform you that, the Board of Directors of the Company at their meeting held today i.e. 29th October, 2026 has, inter alia considered and approved Unaudited Financial Results (as per IND-AS) for the quarter and half year ended on 30th September, 2026. Enclosed herewith a copy of the same along with a copy of Limited Review Report dated 29th October, 2026 received from Vora & Associates, Chartered Accountants, Statutory Auditors of the Company with respect to Unaudited Financial Results for the quarter and half year ended on 30th September, 2026 FOR COLINZ LABORATORIES LTD VIJAYA MANI DIRECTOR DIN: 11363910

Colinz Laboratories Financials

Colinz Laboratories Technicals

EMA & SMA

Current Price
₹65.50
-2 (-2.96%)
pointer
  • Bearish Moving Average 14
  • Bullish Moving Average 2
  • 20 Day
  • ₹68.80
  • 50 Day
  • ₹70.40
  • 100 Day
  • ₹69.40
  • 200 Day
  • ₹64.80

Resistance and Support

66.17 Pivot Speed
  • R3 68.80
  • R2 68.20
  • R1 66.80
  • S1 64.80
  • S2 64.20
  • S3 62.80

Colinz Laboratories Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-10-29 Quarterly Results
2026-07-30 Quarterly Results
2026-04-29 Quarterly Results
2026-01-24 Quarterly Results
2026-01-17 Others

Colinz Laboratories Shareholding Pattern

50.6%
49.4%
0%

Colinz Laboratories FAQs

Colinz Laboratories share price is ₹65 As on 19 November, 2026 | 08:09

The Market Cap of Colinz Laboratories is ₹16.5 Cr As on 19 November, 2026 | 08:09

The P/E ratio of Colinz Laboratories is 5.9 As on 19 November, 2026 | 08:09

The PB ratio of Colinz Laboratories is 1.3 As on 19 November, 2026 | 08:09

The 52 week High & Low of Colinz Laboratories is ₹87.9/₹36.6 respectively As on 19 November, 2026 | 08:09

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23